Tag: Targeted therapy for lung cancer

Home / Targeted therapy for lung cancer

Categories

Lazertinib with amivantamab-vmjw is approved by the USFDA for non-small lung cancer

August 2024: The Food and Drug Administration (FDA) has granted approval for the use of lazertinib (Lazcluze, Janssen Biotech, Inc.) in combination with amivantamab-vmjw (Rybrevant, Janssen Biotech, I...
targeted-therapy-for-lung-cancer

Scan the code